{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T17:58:41Z","timestamp":1781027921745,"version":"3.54.1"},"reference-count":44,"publisher":"BMJ","issue":"8","license":[{"start":{"date-parts":[[2020,8,29]],"date-time":"2020-08-29T00:00:00Z","timestamp":1598659200000},"content-version":"unspecified","delay-in-days":28,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"published-print":{"date-parts":[[2020,8]]},"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Hepatitis C virus (HCV) is a global public health threat, and novel models of care are required to treat those currently or previously at highest risk of infection, particularly persons who inject drugs (PWID; ever injected), as conventional healthcare models do not have the reach to deliver cure of HCV to disadvantaged, disproportionately affected communities. In Western Europe and Australasia, it is estimated that HCV affects between 0.4% and 1.0% of the regions\u2019 populations, accordingly, it affects between 0.4% and 0.7% of the populations of countries in this study (Scotland, Wales and Australia).<jats:underline>R<\/jats:underline>eaching m<jats:underline>E<\/jats:underline>thadone users<jats:underline>A<\/jats:underline>ttending<jats:underline>C<\/jats:underline>ommunity p<jats:underline>H<\/jats:underline>armacies with HCV (REACH HCV) will evaluate community pharmacy-based diagnostic outreach and HCV treatment against conventional HCV testing and treatment pathways for clients receiving opioid substitution therapy (OST) in community pharmacies.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods and analysis<\/jats:title><jats:p>REACH HCV is an international multicentre cluster randomised controlled trial with sites in Scotland, Wales and Australia. The sites are community pharmacies which are randomised equally to one of two pathways: the pharmacy intervention pathway or the education-only (control) pathway. Participants are recruited from OST clients in these pharmacies.<\/jats:p><jats:p>In the pharmacy intervention pathway, participants receive a rapid point-of-care HCV PCR test in their pharmacy by a study outreach nurse. If positive, direct-acting antivirals (DAAs) are delivered to participants via their pharmacist in line with their OST schedule.<\/jats:p><jats:p>In the education-only pathway, pharmacists counsel OST clients on HCV and refer them to the nearest nurse-led clinic or general practitioner offering HCV testing according to standard care protocols. If positive, DAAs are delivered as in the intervention pathway.<\/jats:p><jats:p>The primary endpoint for both pathways is sustained viral response at 12 weeks post-treatment . Secondary outcomes are: cost-efficacy by pathway; participants tested by pathway; adherence to therapy by pathway and impact of blood test results on treatment decisions.<\/jats:p><jats:p>A statistical analysis plan will be finalised prior to data lock. Analysis will be by intention to treat (ITT) to show superiority. Modified ITT analysis will also be undertaken to explore the steps in the pathways.<\/jats:p><\/jats:sec><jats:sec><jats:title>Ethics and dissemination<\/jats:title><jats:p>The trial received ethical favourable opinion from the East of Scotland Research Ethics Committee 2 (19\/ES\/0025) for UK sites and approval from the Alfred Hospital Ethics Committee (148\/19) for Australian sites and complies with principles of Good Clinical Practice. Final results will be presented in peer-reviewed journals and at relevant conferences.<\/jats:p><\/jats:sec><jats:sec><jats:title>Trial registration number<\/jats:title><jats:p>ClinicalTrials.gov Registry<jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" specific-use=\"clinicaltrial pre-results\" xlink:href=\"NCT03935906\">NCT03935906<\/jats:ext-link>.<\/jats:p><\/jats:sec><jats:sec><jats:title>Protocol version<\/jats:title><jats:p>V.4.0\u201419 March 2020.<\/jats:p><\/jats:sec>","DOI":"10.1136\/bmjopen-2019-036501","type":"journal-article","created":{"date-parts":[[2020,8,31]],"date-time":"2020-08-31T07:10:53Z","timestamp":1598857853000},"page":"e036501","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":11,"title":["Reaching mEthadone users Attending Community pHarmacies with HCV: an international cluster randomised controlled trial protocol (REACH HCV)"],"prefix":"10.1136","volume":"10","clinical-trial-number":[{"clinical-trial-number":"nct03935906","registry":"10.18810\/clinical-trials-gov","type":"preResults"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7586-7712","authenticated-orcid":false,"given":"Christopher","family":"Byrne","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4772-2388","authenticated-orcid":false,"given":"Andrew","family":"Radley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah Karen","family":"Inglis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lewis J Z","family":"Beer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicki","family":"Palmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5932-3491","authenticated-orcid":false,"given":"Minh Duc","family":"Pham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brendan","family":"Healy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph S","family":"Doyle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Donnan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John F","family":"Dillon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2020,8,30]]},"reference":[{"key":"2020083100101459000_10.8.e036501.1","unstructured":"World Health Organisation . Global health sector strategy on viral hepatitis 2016-2021, 2016. Available: www.who.int\/hepatitis\/strategy2016-2021\/ghss-hep\/en\/ [Accessed Jun 2019]."},{"key":"2020083100101459000_10.8.e036501.2","first-page":"161","article-title":"Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study","volume":"2","year":"2018","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2020083100101459000_10.8.e036501.3","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2017-021443"},{"key":"2020083100101459000_10.8.e036501.4","unstructured":"Health Protection Scotland . Blood borne viruses and sexually transmitted infections, 2017. Available: www.hps.scot.nhs.uk\/ [Accessed Jun 2019]."},{"key":"2020083100101459000_10.8.e036501.5","unstructured":"Kirby Institute . HIV, viral hepatitis and sexually transmissible infections in Australia: annual surveillance report 2018, 2018. Available: www.kirby.unsw.edu.au [Accessed Jun 2019]."},{"key":"2020083100101459000_10.8.e036501.6","unstructured":"Welsh Government . Substance misuse treatment framework health and wellbeing compendium, 2013. Available: www.wales.nhs.uk\/sitesplus\/888\/opendoc\/238900 [Accessed Jun 2019]."},{"key":"2020083100101459000_10.8.e036501.7","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.drugpo.2017.05.042","article-title":"DOT-C: a cluster randomised feasibility trial evaluating directly observed anti-HCV therapy in a population receiving opioid substitute therapy from community pharmacy","volume":"47","author":"Radley","year":"2017","journal-title":"Int J Drug Policy"},{"key":"2020083100101459000_10.8.e036501.8","unstructured":"Health Protection Scotland . Needle exchange surveillance initiative (NESI) 2008-09 to 2017-18, 2018. Available: www.hps.scot.nhs.uk [Accessed Jun 2019]."},{"key":"2020083100101459000_10.8.e036501.9","unstructured":"Heard S , Iversen J , Geddes L , et al . Australian needle syringe program survey national data report 2013-2017: prevalence of HIV, HCV and injecting and sexual behaviour among NSP Attendees, 2018. Available: www.kirby.unsw.edu.au\/ [Accessed Jun 2019]."},{"key":"2020083100101459000_10.8.e036501.10","unstructured":"Public Health England . Hepatitis C in the UK: 2019 report, 2019. Available: https:\/\/assets.publishing.service.gov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/831155\/Hepatitis_C_in_the_UK_2019_report.pdf [Accessed Oct 2019]."},{"key":"2020083100101459000_10.8.e036501.11","unstructured":"Scottish Health Protection Network . Recommendations on hepatitis C virus case finding and access to care: report of the National Short-life Working group, 2018. Available: https:\/\/www.hps.scot.nhs.uk\/web-resources-container\/recommendations-on-hepatitis-c-virus-case-finding-and-access-to-care\/ [Accessed Jun 2019]."},{"key":"2020083100101459000_10.8.e036501.12","unstructured":"Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine . National hepatitis C testing policy, 2017. Available: www.testingportal.ashm.org.au\/hcv [Accessed Jun 2019]."},{"key":"2020083100101459000_10.8.e036501.13","doi-asserted-by":"publisher","DOI":"10.1136\/flgastro-2016-100776"},{"key":"2020083100101459000_10.8.e036501.14","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.jcv.2014.09.004","article-title":"Uptake of hepatitis C specialist services and treatment following diagnosis by dried blood spot in Scotland","volume":"61","author":"McAllister","year":"2014","journal-title":"J Clin Virol"},{"key":"2020083100101459000_10.8.e036501.15","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1002\/hep.30501","article-title":"The hepatitis C virus care continuum: linkage to hepatitis C virus care and treatment among patients at an urban health network, Philadelphia, PA","volume":"70","author":"Coyle","year":"2019","journal-title":"Hepatology"},{"key":"2020083100101459000_10.8.e036501.16","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.ebiom.2016.08.035","article-title":"The population level cascade of care for hepatitis C in British Columbia, Canada: the bc hepatitis testers cohort (BC-HTC)","volume":"12","author":"Janjua","year":"2016","journal-title":"EBioMedicine"},{"key":"2020083100101459000_10.8.e036501.17","unstructured":"Scottish Executive . Hepatitis C action plan for Scotland phase 1: September 2006 \u2013 August 2008, 2006. Available: https:\/\/www.webarchive.org.uk\/wayback\/archive\/20180516085706\/http:\/\/www.gov.scot\/Publications\/2006\/09\/15093626\/0 [Accessed Jun 2019]."},{"key":"2020083100101459000_10.8.e036501.18","unstructured":"Scottish Government . Sexual health and blood borne virus framework: 2015-2020 update, 2015. Available: https:\/\/www.gov.scot\/publications\/sexual-health-blood-borne-virus-framework-2015-2020-update\/ [Accessed Jun 2019]."},{"key":"2020083100101459000_10.8.e036501.19","unstructured":"Welsh Assembly Government . Blood borne viral hepatitis action plan for Wales 2010-2015, 2010. Available: http:\/\/www2.nphs.wales.nhs.uk:8080\/SubstanceMisuseDocs.nsf\/5633c1d141208e8880256f2a004937d1\/6a249ea7775f3f0b80257c5b0055c9db\/$FILE\/Blood%20Borne%20Viral%20Hepatitis%20Action%20Plan%20for%20Wales%202010-2015.pdf [Accessed Jun 2019]."},{"key":"2020083100101459000_10.8.e036501.20","unstructured":"Department of Health,, Australian Government . Fifth national hepatitis C strategy, 2018. Available: https:\/\/www.health.gov.au\/internet\/main\/publishing.nsf\/Content\/health-publicat.htm [Accessed Jun 2019]."},{"key":"2020083100101459000_10.8.e036501.21","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.drugpo.2018.04.004","article-title":"Stigma at every turn: health services experiences among people who inject drugs","volume":"57","author":"Paquette","year":"2018","journal-title":"Int J Drug Policy"},{"key":"2020083100101459000_10.8.e036501.22","doi-asserted-by":"publisher","DOI":"10.1093\/pubmed\/fdv143"},{"key":"2020083100101459000_10.8.e036501.23","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1093\/pubmed\/fdw138","article-title":"'Standing outside the Junkie Door'-service users' experiences of using community pharmacies to access treatment for opioid dependency","volume":"39","author":"Radley","year":"2017","journal-title":"J Public Health"},{"key":"2020083100101459000_10.8.e036501.24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.drugpo.2018.12.008","article-title":"Application of a discrete choice experiment approach to support the design of a hepatitis C testing service in primary care","volume":"65","author":"Radley","year":"2019","journal-title":"Int J Drug Policy"},{"key":"2020083100101459000_10.8.e036501.25","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s10389-016-0714-y","article-title":"Community pharmacy-based opiate substitution treatment and related health services: a study of 508 patients and 111 pharmacies","volume":"24","author":"Laird","year":"2016","journal-title":"J Public Health"},{"key":"2020083100101459000_10.8.e036501.26","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/S2468-1253(18)30304-2","article-title":"Direct-Acting antiviral treatment for hepatitis C among people who use or inject drugs: a systematic review and meta-analysis","volume":"3","author":"Hajarizadeh","year":"2018","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2020083100101459000_10.8.e036501.27","unstructured":"TCTU . Tayside clinical trials unit, 2014. Available: https:\/\/www.ahspartnership.org.uk\/tasc\/tayside-clinical-trials-unit [Accessed Oct 2018]."},{"key":"2020083100101459000_10.8.e036501.28","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2017-315783"},{"key":"2020083100101459000_10.8.e036501.29","doi-asserted-by":"crossref","first-page":"268","DOI":"10.5694\/mja16.00106","article-title":"Australian recommendations for the management of hepatitis C virus infection: a consensus statement","volume":"204","author":"Thompson","year":"2016","journal-title":"Med J Aust"},{"key":"2020083100101459000_10.8.e036501.30","doi-asserted-by":"publisher","DOI":"10.1016\/0168-8510(90)90421-9"},{"key":"2020083100101459000_10.8.e036501.31","doi-asserted-by":"publisher","DOI":"10.1016\/0168-8510(96)00822-6"},{"key":"2020083100101459000_10.8.e036501.32","doi-asserted-by":"publisher","DOI":"10.3109\/07853890109002087"},{"key":"2020083100101459000_10.8.e036501.33","doi-asserted-by":"publisher","DOI":"10.1007\/s11136-011-9903-x"},{"key":"2020083100101459000_10.8.e036501.34","doi-asserted-by":"publisher","DOI":"10.1007\/s11136-012-0322-4"},{"key":"2020083100101459000_10.8.e036501.35","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1007\/s40273-018-0642-5","article-title":"A systematic review of studies comparing the measurement properties of the three-level and five-level versions of the EQ-5D","volume":"36","author":"Buchholz","year":"2018","journal-title":"Pharmacoeconomics"},{"key":"2020083100101459000_10.8.e036501.36","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1007\/s40273-018-0623-8","article-title":"Is EQ-5D-5L better than EQ-5D-3L? A head-to-head comparison of descriptive systems and value sets from seven countries","volume":"36","author":"Janssen","year":"2018","journal-title":"Pharmacoeconomics"},{"key":"2020083100101459000_10.8.e036501.37","unstructured":"National Institute for Health and Care Excellence . Patient group directions, 2017. Available: https:\/\/www.nice.org.uk\/guidance\/MPG2 [Accessed Aug 2019]."},{"key":"2020083100101459000_10.8.e036501.38","unstructured":"NHS Tayside . Pharmaceutical care of patients receiving treatment for hepatitis C infection, 2016. Available: https:\/\/www.communitypharmacy.scot.nhs.uk\/nhs-boards\/nhs-tayside\/pharmacy-services\/hepatitis-c-information\/ [Accessed Jun 2019]."},{"key":"2020083100101459000_10.8.e036501.39","unstructured":"Public Health Wales . Harm reduction database Wales: blood borne virus testing and treatment in community settings 2017-18, 2017. Available: http:\/\/www.wales.nhs.uk\/sitesplus\/documents\/888\/BBV%20Annual%20report%202017-18%20FOR%20PUBLICATION.pdf [Accessed Jun 2019]."},{"key":"2020083100101459000_10.8.e036501.40","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1017\/S0950268811001634","article-title":"Spatial mapping of hepatitis C prevalence in recent injecting drug users in contact with services","volume":"140","author":"Harris","year":"2012","journal-title":"Epidemiol Infect"},{"key":"2020083100101459000_10.8.e036501.41","doi-asserted-by":"publisher","DOI":"10.1002\/hep.24656"},{"key":"2020083100101459000_10.8.e036501.42","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2013-003153"},{"key":"2020083100101459000_10.8.e036501.43","doi-asserted-by":"publisher","DOI":"10.3310\/hta19880"},{"key":"2020083100101459000_10.8.e036501.44","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2017-018647"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2019-036501","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,6]],"date-time":"2023-10-06T14:50:30Z","timestamp":1696603830000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2019-036501"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8]]},"references-count":44,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2020,8,30]]},"published-print":{"date-parts":[[2020,8]]}},"alternative-id":["10.1136\/bmjopen-2019-036501"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2019-036501","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8]]}}}